Fig 1.
Model structure.
Table 1.
Age and risk level specific demographic and epidemiological parameters.
Table 2.
Effectiveness of PCV13 and PPSV23a.
Table 3.
Maximum herd effect in year 5 of modelling (absolute in %).
Table 4.
Age and risk level specific medical and non-medical costsb.
Table 5.
Age and risk level specific utilities.
Table 6.
Overview of current STIKO recommendation and hypothetical strategies (#1 to#3).
Table 7.
Incremental cost-effectiveness ratios (ICER) over all scenarios (mean values).
Table 8.
Proportion of simulations (%) in the quadrants of the ICER scatterplot.